Skip to main content

Advertisement

Table 1 Patient characteristics

From: Fecal microbiota transplantation against intestinal colonization by extended spectrum beta-lactamase producing Enterobacteriaceae: a proof of principle study

# Age Sex BMI (kg/m2)a Comorbidity ESBL-Producer ESBL-neg.b after 1st FMTc ESBL-neg. after 2nd FMT Donor FMT 1 Donor FMT 2
1 58 M 19 ESRDd, PDe, CVDf E. coli g Y 1
2 47 M 27 Tetraplegia, rUTIh E. coli N 1
3 65 M 25 Renal Txj, rUTI E. coli N N 1 1
4 61 M 24 rUTI K. p j N 1
5 29 F 35 rUTI E. coli N Y 1 2
6 56 F 28 RUTI E. coli N N 1 2
7 70 F 28 Renal Tx, rUTI K. p, E. coli N N 1 2
8 59 F 20 Renal Tx, rUTI, HBVk E. coli Y 1
9 61 F 28 rUTI E. coli N Y 1 1
10 57 F 26 ESRD, rUTI E. coli N 2
11 76 F 23 rUTI E. coli Y 2
12 70 M 24 Renal Tx, rUTI, T2Dl E. coli N 1
13 59 F 29 Renal Tx K. p N N 1 1
14 58 F 36 rUTI E. coli N Y 1 2
15 21 F 24 rUTI E. coli N 1
  1. aBody mass index, b extended-spectrum beta lactamase producer-negative, c fecal microbiota transplantation, d end-stage renal disease, e peritoneal dialysis, f cardiovascular disease, g Escherichia coli, h recurring urinary tract infections, i transplant, j Klebsiella pneumoniae, k Hepatitis B virus, l type 2 diabetes. Patient 7 had (only) K. pneumoniae before the 1st FMT and (only) E. coli before the second FMT